permax

基本解釋

Permax was approed in 1988 for Eli Lilly and Company as an adjunctie therapy with leodopa in Parkinson's disease. alular heart disease was first described in association with pergolide in 2002.
Permax是伊萊利利公司于1988年獲得批準(zhǔn)的、作為輔助治療藥物與左旋多巴用于帕金森氏癥的治療。
In 2003, FDA asked Lilly to add alulopathy (abnormality of cardiac ales) to the warnings section of Permax labeling, at which time a Dear Healthcare Practitioner letter was sent by Lilly.
首次關(guān)于培高利特與瓣膜性心臟疾病相關(guān)的報(bào)道是在2002年，2003年FDA要求伊萊利利公司在培高利特標(biāo)簽的警告部分添加心臟瓣膜疾病的警示語，同時(shí)該公司發(fā)出了“致健康從業(yè)者信”。